Eli Lilly's Alzheimer's Drug to Outsell Rival, Hitting $5B by 2030

By Bill Bullington

ᐧ

4/22, 06:25 EDT

Projected global revenues for Leqembi are expected to grow steadily from 2024, reaching over $2 billion by 2030, while donanemab is forecasted to see a more dramatic increase, surpassing $5 billion in the same timeframe.
The revenue projections for donanemab are more than double those of Leqembi by 2030, indicating higher market expectations for Eli Lilly's Alzheimer's drug compared to the Eisai/Biogen collaboration.